Does Weed Shorten Your Lifespan?

Cannabis use is statistically associated with a higher risk of dying from any cause, though the size of that risk and the pathways behind it are more complicated than a simple yes-or-no answer suggests. A 2025 meta-analysis pooling data from 14 cohort studies found that people who use cannabis had roughly one and a half times the risk of all-cause mortality compared to non-users. That number sounds alarming, but the research behind it is tangled with confounders, and the risk varies enormously depending on how much you use, how you consume it, your sex, and what other health conditions you carry.

What the Overall Mortality Data Actually Shows

The most comprehensive look at whether cannabis shortens life comes from a 2025 systematic review and meta-analysis that combined 14 cohort studies. The pooled relative risk for all-cause mortality among cannabis users compared to non-users was 1.53, meaning users were about 53% more likely to die during the follow-up periods studied.¹ That is a real signal, but the studies feeding into it had extremely high variability, which means the true number could be meaningfully higher or lower. The authors flagged this uncertainty themselves.

A large 2024 study that followed Americans over decades broke the question down by sex and found that the picture is not the same for men and women. After adjusting for factors like age, smoking, alcohol, and body weight, heavy cannabis use was not significantly linked to all-cause mortality in men. In women, though, heavy lifetime use was associated with roughly two and a half times the risk of dying from cardiovascular disease compared to women who never used.² Cancer mortality was elevated in female heavy users too, though the confidence intervals were wide enough that the finding did not reach statistical significance. The sex difference in cardiovascular mortality is striking and still not fully explained.

The Heart and Stroke Connection

If cannabis does shorten lives, the cardiovascular system looks like a leading suspect. A study using data from hundreds of thousands of U.S. adults found that daily cannabis users had about 25% higher odds of heart attack and 42% higher odds of stroke compared to non-users. The relationship was dose-dependent: the more frequently someone used, the higher the odds climbed. And the association held regardless of whether cannabis was smoked, eaten, or vaped.³

A separate analysis published in a leading cardiology journal confirmed the pattern and added an important wrinkle. Among people who had never smoked tobacco, daily cannabis use was linked to roughly 49% higher odds of heart attack and more than double the odds of stroke.⁴ That finding matters because it suggests the heart risk is not simply explained by tobacco use, which many cannabis smokers also engage in. Something about cannabis itself, or at least how people use it, appears to stress the cardiovascular system independently.

The evidence on stroke in younger adults is less clear-cut. A case-control study specifically looking at early-onset stroke found that after adjusting for tobacco and other risk factors, marijuana use was not significantly linked to ischemic stroke in young adults, though there was a trend toward higher risk among people who smoked at least weekly.⁵ So while the population-level data points strongly toward cardiovascular harm, the risk in any given individual depends heavily on their overall health profile and how heavily they use.

Lungs and Cancer

You might assume that smoking cannabis regularly would carry lung cancer risk similar to tobacco. The reality is surprisingly murky. Despite sharing many of the same toxic compounds found in tobacco smoke, including polycyclic aromatic hydrocarbons and volatile organic compounds, the epidemiological evidence connecting cannabis smoking to lung cancer remains inconclusive.⁶ Some studies suggest elevated risk among heavy users, especially those who also smoke tobacco, but others find no significant link at all.

A review in a thoracic oncology journal put it bluntly: cannabis smoking has not been proved to cause lung cancer, but the evidence is limited by small studies, self-reporting bias, the small number of truly heavy cannabis-only smokers studied, and the confounding presence of tobacco use in many participants.⁷ It is possible that cannabis carries some lung cancer risk that existing studies are simply too small or too messy to detect. But it is also possible that cannabinoids interact with lung tissue differently than tobacco compounds do. The honest answer is that we do not know yet.

One cancer type where the evidence is more convincing is testicular germ cell tumors. A 2025 meta-analysis found that current cannabis use was associated with 62% higher odds of developing these tumors, and long-term use of ten years or more raised the odds by about 68%.⁸ An earlier meta-analysis found that weekly cannabis use was linked to roughly two and a half times the odds of developing a specific subtype called non-seminoma.⁹ This is a relatively rare cancer, so even a doubled risk translates to a small absolute number. But for young men who are the primary demographic for both heavy cannabis use and testicular cancer, it is worth knowing about.

Cannabis and Biological Aging

One of the more unsettling findings in recent cannabis research has nothing to do with any single disease. It involves how cannabis changes the chemical markers on your DNA that are associated with aging. A study of young adults found that people who had ever used marijuana showed about six months of accelerated biological aging on an epigenetic clock, and recent users showed roughly 20 months of acceleration.¹⁰ Each additional year of cumulative use added about two and a half months of biological aging on the same measure.

What makes this finding especially interesting is that some of these DNA methylation changes do not seem to reverse when people quit. A 2025 study found that cannabis smokers showed persistent disruptions to their epigenome even after stopping, and those changes were concentrated in pathways linked to aging and cancer.¹¹ A separate study of long-term users at midlife confirmed that several specific DNA methylation sites remained altered in persistent cannabis users even after accounting for tobacco, alcohol, and other drug use.¹²

Epigenetic aging does not necessarily translate directly into shorter life, and these are relatively new tools in the research arsenal. But the pattern is consistent enough across multiple studies that it suggests cannabis use leaves a lasting biological footprint beyond what you can see in a mirror or feel in your lungs.

Mental Health, Suicide Risk, and Indirect Mortality

Cannabis does not have to cause a heart attack or cancer to shorten a life. Psychiatric effects can contribute to premature death indirectly, and the evidence here is sobering. An umbrella review covering multiple systematic reviews found that cannabis use is associated with more severe depression, more psychotic symptoms, and higher rates of suicidal behavior. People with psychosis who use cannabis were about 2.6 times more likely to attempt suicide than those who did not use, and even non-psychotic cannabis users showed elevated risk.¹³

The risk appears dose-dependent. A 2025 review found that daily cannabis use was associated with about 2.7 times the odds of suicidal behavior, and high-potency cannabis carried even greater risk.¹⁴ Among people who experienced a first episode of cannabis-induced psychosis, those who continued using cannabis had persistently higher depression and suicidality scores at three and nine months, along with slower recovery from psychotic symptoms and much higher relapse rates compared to those who stopped using.¹⁵

None of this means cannabis inevitably causes psychiatric harm, and most users never experience psychosis. But for the subset of people who are vulnerable, continued use can create a dangerous feedback loop between worsening mental health and continued self-medication.

Cannabinoid Hyperemesis Syndrome and Acute Crises

A condition that was barely recognized twenty years ago has become increasingly common in emergency departments. Cannabinoid hyperemesis syndrome, or CHS, causes cycles of severe, uncontrollable vomiting in chronic heavy users. The vomiting itself is miserable, but the real danger comes from what follows: profound dehydration that can cause acute kidney injury and dangerous drops in electrolytes.¹⁶

Patients with CHS often compulsively take hot showers or baths, which provides temporary relief but can worsen dehydration. A case series found that the combination of persistent vomiting and constant hot bathing puts CHS patients at significant risk of kidney failure.¹⁷ Vomiting episodes typically last one to two days and can require hospitalization.¹⁸ CHS is not a leading cause of death, but it is a genuine medical emergency that can become life-threatening if untreated, and it exclusively affects people who use cannabis heavily and frequently.

Does How You Consume It Matter?

Most of the lung-specific risks of cannabis come from inhaling combustion products, so it is reasonable to wonder whether switching consumption methods changes the picture. A review of the evidence on vaporizers found that vaping cannabis can reduce carbon monoxide exposure, lower chronic respiratory symptoms, and decrease exposure to several toxins compared to smoking, while producing similar blood THC levels and subjective effects.¹⁹ That makes vaping a plausible harm-reduction strategy for the respiratory system, though it does nothing to address the cardiovascular, psychiatric, or epigenetic risks discussed above. And the long-term safety data on cannabis vaporizers is still thin.

Edibles sidestep the respiratory issue entirely but introduce their own problems. They take longer to kick in, which makes it easier to overconsume, and the resulting intoxication can be more intense and longer-lasting. The cardiovascular data mentioned earlier showed that the association between cannabis and heart attack held even for non-smoked forms, so edibles are not a cardiovascular free pass.

It is also worth noting that the cannabis people are using today is far more potent than what was studied in many older research programs. In the 1970s, THC content was typically around 1 to 2 percent; common flower today runs 15 to 20 percent, and concentrates can contain 80 to 90 percent THC.²⁰ This potency escalation means that findings from studies conducted a decade or two ago may underestimate the risks of today’s products.

Synthetic Cannabinoids Are a Different Story Entirely

Any discussion of cannabis and mortality needs to distinguish natural cannabis from synthetic cannabinoids, sometimes sold as “Spice” or “K2.” These lab-made compounds bind to the same brain receptors as THC but with much higher potency and activity, producing far more severe and unpredictable effects.²¹ Reported adverse effects include respiratory difficulty, dangerously high heart rates, chest pain, acute kidney failure, severe psychosis, and death.²² When news reports describe someone dying from “marijuana,” synthetic cannabinoids are often involved. They are genuinely dangerous in a way that natural cannabis rarely is acutely.

Contaminants and What You Do Not Know You Are Inhaling

In unregulated or poorly regulated markets, the cannabis itself may be the least dangerous thing in the product. A review of cannabis contaminants identified microbes, heavy metals, and pesticides as common adulterants. Their direct human health effects are poorly quantified, but potential harms include infection, cancer risk from heavy metal exposure, and reproductive damage.²³ This is a meaningful variable in the lifespan question: someone buying tested, regulated cannabis in a legal dispensary faces a different risk profile from someone buying from an unregulated source where lead, cadmium, or banned pesticides may be present.

Drug Interactions You Might Not Expect

If you use cannabis while taking prescription medications, there is an underappreciated risk that rarely makes it into casual conversations about weed. THC and CBD interact with the liver enzymes that metabolize many common drugs, which can raise or lower blood levels of those medications to dangerous degrees.²⁴ A systematic review found reports involving 16 different narrow-therapeutic-index medications, meaning drugs where small changes in blood level can cause serious harm. The most widely reported interactions involved blood thinners like warfarin, the seizure medication valproate, and immunosuppressants like tacrolimus. In more than half of the cases reviewed, clinicians discovered an unexpected serum level of the prescribed drug.²⁵ For someone on warfarin, this could mean uncontrolled bleeding. For someone on an immunosuppressant after an organ transplant, it could mean rejection.

Cannabis as an Opioid Substitute

The lifespan conversation would be incomplete without acknowledging that for some people, cannabis use is not adding a risk but replacing a worse one. A survey of chronic pain patients found that medical cannabis use was associated with a 64% decrease in opioid use, along with fewer medication side effects and improved quality of life.²⁶ Given that the majority of opioid overdose deaths occur among patients with legitimate prescriptions, the possibility that some people use cannabis as a less lethal alternative to opioids complicates any simple calculation about whether cannabis shortens life at a population level.²⁷

This does not mean cannabis is a safe or effective pain medication for everyone. The evidence for its analgesic properties is still limited. But for the subset of chronic pain patients who find it helpful, the net mortality risk of switching from opioids to cannabis could plausibly be negative, meaning it extends their expected lifespan rather than shortening it.

Cognitive Decline and Dementia

Many regular users worry about long-term brain health, and the fear that cannabis might accelerate dementia is common. A large 2025 study using both observational and genetic analysis methods found no significant association between cannabis use disorder and dementia risk in older adults.²⁸ Genetic analyses designed to test whether the relationship could be causal also came up empty. That said, isolated case reports do exist describing early-onset neurodegenerative conditions in heavy cannabis users, so an absence of population-level risk does not guarantee individual safety.²⁹

Starting Young Changes the Equation

The age at which someone begins using cannabis matters more than most people realize. A longitudinal study that followed urban adolescents into their early forties found that heavy marijuana use by age 16 had broad and lasting consequences. Those heavy adolescent users were about 1.8 times as likely to be unmarried and nearly twice as likely to be living below the poverty line at age 42. They also had significantly lower income in midlife, with much of the effect running through higher rates of dropping out of high school and escalating adult drug use patterns.³⁰ While poverty and lower educational attainment do not appear in a blood test, they are among the strongest predictors of shorter lifespan. Adolescent cannabis use may shorten lives not through any single disease pathway but by derailing the social and economic trajectory that determines health for decades.

Driving and Accident Risk

Cannabis impairs reaction time, attention, and decision-making while intoxicated, so you might expect a clear link to fatal motor vehicle accidents. The reality is muddier. A review comparing cannabis and alcohol effects on driving found that while the evidence unanimously supports alcohol as a crash risk factor, the epidemiological data on cannabis and accidents has been inconclusive.³¹ Part of the reason may be that cannabis-impaired drivers tend to compensate by driving more slowly and cautiously, whereas alcohol-impaired drivers tend to do the opposite. This does not mean driving high is safe. It means the population-level data has been harder to pin down than for alcohol, partly because cannabis stays detectable in blood long after impairment has worn off, making it difficult to know whether a driver who tests positive was actually impaired at the time of a crash.